What Is Retatrutide? The Triple Agonist Explained

Retatrutide is a once-weekly injectable peptide developed by Eli Lilly that simultaneously activates three hormone receptors — GLP-1, GIP, and glucagon — making it the most mechanistically advanced weight-loss drug ever tested in human clinical trials. No other approved or investigational weight-loss medication hits all three targets at once.

What Is Retatrutide, Exactly?

Retatrutide is a synthetic peptide — a short chain of amino acids engineered to mimic and amplify the signals of three gut hormones your body already produces. Its internal Eli Lilly designation is LY3437943, and while it doesn't yet have a brand name, it's sometimes informally called a "triple GLP" or GLP-3 agonist (though that's a shorthand, not an official classification).

The three receptors it targets:

• GLP-1 (glucagon-like peptide-1): Slows gastric emptying, reduces appetite signals in the brain, stimulates insulin release in response to food
• GIP (glucose-dependent insulinotropic polypeptide): Amplifies insulin response to meals, improves insulin sensitivity, and may directly support fat cell regulation
• Glucagon receptor: Increases energy expenditure and drives fatty acid oxidation — essentially telling your body to burn more stored fat

This triple action is why the results seen in trials are so far beyond anything achieved by semaglutide (Ozempic/Wegovy) or tirzepatide (Mounjaro/Zepbound).

The Brand Name Question

As of March 2026, retatrutide has no approved brand name. Eli Lilly is running it through Phase 3 clinical trials under the trial name TRIUMPH. When and if it receives approval, Eli Lilly will assign a commercial brand name — but that hasn't happened yet. Online, you'll see it referred to by its INN name (retatrutide) or its compound ID (LY3437943).

Who Makes Retatrutide?

Retatrutide is developed exclusively by Eli Lilly and Company, the Indianapolis-based pharmaceutical giant that also developed:

• Dulaglutide (Trulicity) — GLP-1 agonist
• Tirzepatide (Mounjaro for diabetes, Zepbound for obesity) — GLP-1/GIP dual agonist
• Retatrutide — GLP-1/GIP/glucagon triple agonist

Each generation has delivered progressively stronger weight-loss outcomes. Retatrutide represents Lilly's third-generation metabolic platform.

How Retatrutide Works: The Mechanism of Action

Understanding retatrutide's mechanism of action (MOA) requires understanding what each receptor does individually — and why combining all three creates an effect that's greater than the sum of its parts.

GLP-1 Receptor Agonism: The Foundation

GLP-1 is released naturally from intestinal cells after you eat. It signals your brain to reduce hunger, slows how quickly food moves through your stomach (increasing satiety), and triggers insulin secretion from the pancreas when blood glucose is elevated. All GLP-1 drugs — from liraglutide to semaglutide to tirzepatide — use this as their base mechanism.

Retatrutide activates GLP-1 receptors with potency similar to semaglutide at the receptor level, but that's just the starting point.

GIP Receptor Agonism: The Amplifier

GIP (glucose-dependent insulinotropic polypeptide) is another gut hormone released after eating. For years, GIP was considered a minor player. Tirzepatide changed that narrative by showing dual GLP-1/GIP activation produced meaningfully better weight loss than GLP-1 alone.

In retatrutide, GIP agonism serves multiple functions:

• Boosts insulin response to meals (additive to GLP-1 effect)
• May improve peripheral insulin sensitivity in muscle tissue
• Research suggests GIP activation can reduce GLP-1-associated nausea, potentially improving tolerability

Glucagon Receptor Agonism: The Differentiator

This is where retatrutide separates itself from everything else. Glucagon is typically thought of as the "raise blood sugar" hormone — the counter to insulin. At first glance, activating glucagon receptors sounds counterproductive for diabetes and obesity treatment.

But that framing is incomplete. Glucagon receptors in the liver and fat tissue, when selectively activated:

• Increase hepatic fat oxidation — the liver burns more stored fat
• Raise basal metabolic rate — you expend more calories at rest
• Drive fatty acid mobilization — fat stored in adipose tissue gets released for energy

The key engineering challenge was balancing glucagon activation to get metabolic benefits without the blood sugar-raising effects. Retatrutide's design ensures the GLP-1-mediated insulin response offsets glucagon's glucose-raising tendency, resulting in net metabolic benefit.

This is why retatrutide's weight loss numbers in trials look so different from anything seen before. It's not just eating less — it's also burning more.

Retatrutide HA: What Does That Mean?

You may see "retatrutide HA" in some contexts. HA refers to hyaluronic acid, which is a formulation approach sometimes used to extend peptide half-life or improve subcutaneous absorption. This is a formulation-level detail, not a different drug. The active molecule is the same retatrutide peptide; HA is an excipient consideration in certain delivery systems.

The TRIUMPH Trial: What the Data Actually Shows

The Phase 2 TRIUMPH trial is the primary source of retatrutide's remarkable weight-loss data. Published in the New England Journal of Medicine and presented at major endocrinology conferences, the results stopped the obesity medicine community in its tracks.

Phase 2 TRIUMPH Trial Key Results

Participants: Adults with obesity (BMI ≥30, or ≥27 with at least one weight-related condition) without type 2 diabetes Duration: 48 weeks Design: Randomized, double-blind, placebo-controlled

Weight loss by dose group at 48 weeks:

To put that 24.2% figure in context: a 250-pound person would lose approximately 60 pounds. The highest dose group (12mg) saw roughly one in three participants achieve ≥25% body weight reduction — a threshold previously considered the domain of bariatric surgery.

How That Compares to Phase 2 Data for Other Drugs

• Semaglutide 2.4mg (Wegovy): ~14.9% weight loss at 68 weeks (STEP 1 trial)
• Tirzepatide 15mg (Zepbound): ~22.5% weight loss at 72 weeks (SURMOUNT-1 trial)
• Retatrutide 12mg: ~24.2% weight loss at 48 weeks (TRIUMPH Phase 2)

The duration point matters: retatrutide achieved comparable or greater results in less time and continues to be evaluated in longer Phase 3 trials.

Additional TRIUMPH Findings

• Significant reductions in waist circumference (averaging 20+ cm at highest doses)
• Improvements in blood pressure, triglycerides, and fasting glucose
• Dose-dependent increases in lean mass preservation (fat-free mass)
• Higher doses showed continued weight loss trajectory — the plateau observed with semaglutide was less pronounced

Phase 3 TRIUMPH Trials: Current Status

Eli Lilly is running multiple Phase 3 TRIUMPH trials as of 2026:

• TRIUMPH-1: Obesity without diabetes (primary endpoint: weight loss %)
• TRIUMPH-2: Type 2 diabetes and obesity (glycemic + weight endpoints)
• TRIUMPH-3: Cardiovascular outcomes

The Phase 3 program is substantially larger and will determine the safety and efficacy data required for an FDA submission. Recent Phase 3 top-line data for the diabetes arm showed significant A1c reductions alongside meaningful weight loss, consistent with Phase 2 signals.

Retatrutide vs. Semaglutide vs. Tirzepatide: The Comparison

This is the question most people actually want answered. Here's a direct breakdown:

The Glucagon Advantage in Plain Terms

Think of it this way: semaglutide has one engine. Tirzepatide has two. Retatrutide has three — and the third engine (glucagon) is the one that specifically targets stored fat and metabolic rate. That's the fundamental reason the weight-loss numbers are higher.

The tradeoff — and this is important — is that three mechanisms also means potentially more complexity in side effects and interactions. That's one reason Phase 3 data is necessary before anyone can draw firm conclusions about long-term risk profiles.

Retatrutide Benefits: What People Are Experiencing

Based on the Phase 2 TRIUMPH data and early Phase 3 signals, the benefits associated with retatrutide include:

Weight Loss

The headline benefit. Up to 24.2% total body weight reduction in Phase 2 — numbers that approach what's achievable with bariatric surgery. For context, the clinical threshold for meaningful health outcomes is often cited as 5-10% weight reduction; retatrutide is hitting 3-4x that at maximum doses.

→ For a deeper breakdown, see our retatrutide weight loss guide.

Glycemic Control

Retatrutide significantly reduces HbA1c in people with type 2 diabetes. The combination of GLP-1-mediated insulin secretion and glucagon suppression produces robust blood sugar control. Phase 3 data from the T2D arm shows A1c reductions comparable to or better than current best-in-class options.

Cardiovascular Markers

Participants in TRIUMPH showed improvements in:

• Systolic blood pressure (average reductions of 5-10 mmHg)
• Triglycerides
• HDL cholesterol

Whether these translate to reduced cardiovascular events (like MACE) will require the TRIUMPH-3 cardiovascular outcomes trial.

Liver Fat Reduction

The glucagon receptor component specifically drives hepatic fat oxidation, making retatrutide potentially useful for metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD). This is an area of active investigation.

Waist Circumference Reduction

Average reductions of 20+ cm in waist circumference were observed at the highest doses — a marker of visceral fat reduction, which is more metabolically significant than total body weight.

→ See our full retatrutide before and after results for documented case data.

Availability: Can You Get Retatrutide Right Now?

This is where a lot of people get confused, so let's be clear about where things stand.

Eli Lilly's Retatrutide Is Not Commercially Available

Eli Lilly's retatrutide is in Phase 3 clinical trials. It has not received FDA approval for commercial sale. You cannot get a prescription for it at a pharmacy. Eli Lilly is not selling it.

What Is Available Through Peptide Suppliers

The retatrutide peptide itself — identical in sequence to the clinical compound — is synthesized and made available by peptide suppliers for individuals who want access to the compound outside of the formal clinical trial system. This is the route people take when they want access before commercial approval.

If you're looking to source retatrutide, quality and purity verification is the critical factor. We recommend checking Ascension Peptides as a sourcing option with lab-tested products.

→ See our full retatrutide where to buy guide for a detailed breakdown of sourcing considerations.

Timeline for Commercial Availability

Eli Lilly has not announced a specific FDA submission timeline, but given that Phase 3 trials began in 2023-2024 and typically run 2-3 years, a potential submission window of 2026-2027 is reasonable speculation. This is not guaranteed.

Retatrutide Dosage: The Titration Protocol

Phase 2 and Phase 3 trials use a structured dose escalation to minimize GI side effects. The standard titration used in TRIUMPH trials:

→ For complete dosage tables and titration schedules, see our retatrutide dosage guide.

General trial dosing structure:

• Start: 2mg once weekly for 4 weeks
• Escalate: to 4mg for 4 weeks
• Continue escalating: 6mg → 8mg → 10mg → 12mg (target dose)
• Each step takes 4 weeks minimum

The rationale for slow titration is GI tolerability — nausea and GI discomfort are most common during the escalation phase and typically diminish at stable dose.

Side Effects: What to Know

Retatrutide's side effect profile in clinical trials is broadly consistent with other GLP-1-class drugs, with some nuances:

Most Common Side Effects (Phase 2 Data)

• Nausea — most common, typically during dose escalation
• Vomiting — less common than nausea
• Diarrhea
• Constipation
• Decreased appetite (considered a benefit in this context, but can be significant)

Retatrutide-Specific Considerations

• Elevated resting heart rate: A modest increase in heart rate (~3-5 bpm) was observed, similar to what's seen with semaglutide. This is being monitored in Phase 3.
• Gallbladder events: Rapid weight loss across all GLP-1 class drugs is associated with increased gallstone risk. Retatrutide carries a similar consideration.
• Hypoglycemia: In people without diabetes, hypoglycemia risk is low. In type 2 diabetes trials, the glucose-dependent mechanism of GLP-1 and GIP makes standalone hypoglycemia uncommon unless combined with sulfonylureas or insulin.

Glucagon-Specific Monitoring

Because the glucagon component raises questions about long-term liver and cardiovascular effects at scale, Phase 3 trials include expanded safety monitoring beyond what's standard for GLP-1 drugs. This is a data gap that will be filled by TRIUMPH-3.

→ For a complete side effects breakdown, read our retatrutide side effects guide.

Who Is Retatrutide Right For?

Based on the Phase 2 inclusion criteria and the biology of how retatrutide works, the people most likely to benefit are:

Individuals With Significant Weight to Lose

Retatrutide's trial population had a mean BMI of ~37-40. The drug is designed for people with obesity (BMI ≥30) or overweight with metabolic complications. The dose-dependent response means those who can tolerate the full 12mg will see the most pronounced results.

People Who Haven't Achieved Goals on Semaglutide or Tirzepatide

This is a growing population. Some people plateau on semaglutide or find tirzepatide's results insufficient. The glucagon mechanism in retatrutide specifically targets metabolic rate and hepatic fat in ways those drugs don't, so it's a meaningfully different biological intervention — not just "more of the same."

Type 2 Diabetes With Obesity

Dual goals of glycemic control and weight loss make retatrutide particularly compelling for this population. Phase 3 T2D data shows strong HbA1c reductions alongside the weight loss results.

People With Metabolic Liver Disease (MASLD/NAFLD)

The glucagon component's specific action on hepatic fat makes retatrutide a strong candidate for this indication. Eli Lilly may pursue a separate regulatory pathway for MASLD.

People Who Tolerate GLP-1 Drugs Reasonably Well

If you've had severe reactions to semaglutide (severe vomiting, pancreatitis, severe gastroparesis), retatrutide's similar core mechanism means caution is warranted. The GIP component may reduce some GI side effects, but you're still activating GLP-1 receptors.

Who It's Probably Not Right For

• People with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) — this is a class-wide concern for GLP-1 drugs based on animal data
• Pregnancy or planning pregnancy
• People with severe GI disorders (gastroparesis, inflammatory bowel disease)
• Anyone seeking a mild, low-commitment intervention — this is a potent drug that requires real commitment to titration and lifestyle alignment

The Bigger Picture: Why Retatrutide Matters

Retatrutide isn't just another weight-loss drug. It's a signal of where metabolic medicine is heading — toward increasingly precise, multi-target interventions that work with the body's own hormonal systems rather than blunt suppression.

The progression from GLP-1 alone → GLP-1/GIP → GLP-1/GIP/glucagon has been remarkably linear in terms of results, with each generation delivering meaningfully better outcomes. That raises an obvious question: what comes after the triple agonist?

Eli Lilly and other developers are already working on quadruple agonists targeting additional receptors (including amylin and CCK pathways). But for now, retatrutide is the leading edge.

The 24.2% weight loss figure from Phase 2 — in a randomized, placebo-controlled, double-blind trial — is not marketing copy. It's peer-reviewed data published in the New England Journal of Medicine. That kind of result changes what's clinically possible for people who have struggled with obesity for years or decades.

Frequently Asked Questions

Ready to Learn More?

Retatrutide represents a genuine step-change in what's possible for metabolic health. If you're exploring your options:

• Side Effects Guide — Full breakdown of what to expect and how to manage it
• Dosage & Titration — Complete protocol with dose escalation tables
• Before & After Results — Real documented outcomes
• Weight Loss Deep Dive — How it compares across the full weight-loss landscape
• Where to Source Retatrutide — Quality and verification guide

For a trusted source with lab-verified peptides, check out Ascension Peptides.